Stay informed with the latest updates on coronavirus (COVID-19). Find out more >>


  • See also

    Diabetes Mellitus

    Key points

    1. Hypoglycaemia is a Blood Glucose Level (BGL) low enough to cause signs and/or symptoms of impaired brain function and neurogenic response - generally BGL <3.3 mmol/L
    2. Infants with BGL <2.6 mmol/L and risk factors are at risk of acute and long-term neurological sequelae.
    3. Altered conscious state or seizures warrant prompt BGL assessment and management with a bolus of IV 10% Dextrose (2 mL/kg) or IM glucagon.
    4. A venous blood gas and other diagnostic blood tests are important to identify an underlying cause but should not delay management.


    • Hypoglycaemia is a BGL low enough to cause signs and/or symptoms of impaired brain function and neurogenic response - generally BGL <3.3 mmol/L
    • In neonates <48 hrs old, there is a lack of consensus on what constitutes normal BGL, however, BGL <2.6 warrants immediate intervention
    • Prolonged or recurrent hypoglycaemia, especially with clinical features, can cause long term neurological damage or death
    • Age at presentation can indicate the underlying case:


    Causes of Hypoglycaemia include

    Neonate < 48-72 hrs

    Prem, IUGR, perinatal asphyxia, hypothermia, sepsis, resp distress, diabetic mother, macrosomia, syndrome (eg Beckwith-Wiedemann), pancreatic dysfunction

    Neonate – 2yrs

    Congenital hyperinsulinism (most common cause of persistent hypoglycaemia <2 yrs), inborn errors of metabolism, congenital hormone deficiencies (eg growth hormone deficiency)


    Accelerated starvation (previously known as “ketotic hypoglycaemia”)**, hypopituitarism, growth hormone deficiency


    Insulinoma, adrenal insufficiency, eating disorder

    All ages

    Complication associated with Type 1 Diabetes Mellitus (see Diabetes Mellitus), other illness (eg sepsis, congenital heart disease, tumour, adrenal insufficiency)

    ** Accelerated starvation is a diagnosis of exclusion.  It requires a history of a prolonged fast (usually precipitated by a mild illness), with low BGL in association with ketonuria and/or ketonaemia and normalisation of BGL upon feeding.


    Red flag features in Red


    • Symptoms of hypoglycaemia
      • Palpitations, tremor, anxiety, sweating, hunger, paraesthesia
      • Severe hypoglycaemia - lethargy, irritability, uncharacteristic behaviour, hypothermia, confusion, coma, seizures
      • Neonate <48 hrs - apnoea, hypotonia, jitteriness, poor feeding, high pitched cry
    • Dietary history, fasting/illness and relationship to food
      • Milk products (galactosaemia)
      • Fructose eg juices (hereditary fructose intolerance)
      • Protein (amino acid or organic acid disorders)
    • History of toxin ingestion – in toddlers or young children consider accidental ingestion of alcohol, oral hypoglycaemic agents (sulfonylureas), aspirin, beta blockers, or toxins
    • Increased glucose requirements, eg sepsis, shock, tumours, trauma
    • Past history
      • Neonatal history of hypoglycaemia
      • Episodes suggestive of hypoglycaemia eg undiagnosed seizure disorder
      • Previous gastric surgery, fundoplication (postprandial hypoglycaemia)
    • Family history
      • Consanguinity
      • Unexplained infant deaths (inborn errors of metabolism)
      • Hormonal deficiencies and hyperinsulinism


    • Altered conscious state and seizures
    • Fever or hypothermia
    • Finding related to underlying diagnosis
      • Hepatomegaly and/or hypotonia (inborn error of metabolism)
      • Poor growth and nutrition
      • Dysmorphic (syndrome)


    • First presentation or severe hypoglycaemia should be investigated
    • Infants <48 hrs of age who respond appropriately to enteral feeds are unlikely to need extensive investigations
    • A capillary glucometer reading is unreliable at low readings; hence it is important to confirm that true (laboratory) BGL is <2.6 mmol/L 


    • Venous/capillary blood gas
    • Diagnostic blood tests during the period of hypoglycaemia (either at the initial presentation or during an elective fast) prior to management

    Plasma glucose 1 or 3

    Ketones 1 or 3

    Free fatty acids 1 (FFAs)

    Insulin & C-peptide 3

    Lactate 1 or 3

    Ammonia 2

    Cortisol 3

    Carnitine / Acylcarnitine 2,4

    Amino acids 2

    Electrolytes 2

    Liver Function Test 3

    Growth Hormone 3

    Minimum blood volume 5 mL
    Tubes Required:

    1. 3 x 0.5 mL fluoride oxalate
    2. 3 x 0.5 mL lithium heparin 
    3. 2 x 0.5 mL serum gel tube
    4. Newborn Screening Test (Guthrie) card - send air dried and in envelope, not in a plastic specimen bag

    All tests must go immediately to the laboratory on an ice pillow

    • Urine - first voided urine after hypoglycaemic episode, requesting glucose, ketones, reducing substances and amino and organic acids


    • The aim of treatment is to return BGL to within the normal range (>3.9 mmol/L) through normal nutritional intake. See flow chart
      • Severe symptomatic hypoglycaemia should be corrected with an IV 10% dextrose bolus 2 mL/kg or IM glucagon (Neonate: glucagon 0.03-0.1 mg/kg, <25 kg give ½ vial (0.5 Units), <25 kg give ½ vial (0.5 Units), >25 kg give full vial (1.0 Units))
    • BGL should return to the normal range within 10-15 mins and remain so for 1 hour. Ideally, the child should start to feed and BGL should be rechecked within 30 mins
    • Persistent hypoglycaemia - consider consultation with Endocrinology and/or Metabolic specialist

    Hypoglycaemia -1

     Discharge requirements

    • A cause for hypoglycaemia must be known (or accelerated starvation assumed) prior to discharge
    • Neonates: BGL ≥2.6 for 3 consecutive normal feeds
    • Infants and older children: BGL >3 mmol/L at least 4 hours post feeds/meals
    • Accelerated starvation – parental education regarding prolonged starvation

    Consider consultation with local paediatric team when

    • Child is not responding to first line treatment of food, IV 10 % Dextrose bolus or IM glucagon
    • Neonates

    Consider transfer when

    • Child requiring multiple Dextrose boluses or Dextrose infusion
    • Child requiring care beyond the comfort level of the hospital

    For emergency advice and paediatric or neonatal ICU transfers, call the Paediatric Infant Perinatal Emergency Retrieval (PIPER) Service: 1300 137 650.

    Parent information sheet

    No KHI available - see Diabetic hypoglycaemia

    Interpretation of Test results

       Hypoglycaemia - 2






    <2.6 mmol/L - hypoglycaemia

    (Beta hydroxybutyrate )

    ↓ in:

    • Fatty acid oxidation defect
    • Hyperinsulinaemia


    ↑ in:

    • Metabolic liver disease
    • Glycogen storage disorders
    • Sepsis
    • Prolonged convulsion

    Free fatty acids

    Fatty acid oxidation defect

    Carnitine / acylcarnitine

    Fatty acid oxidation defect


    ↑ in:

    • Organic acidaemias
    • Tyrosinaemia
    • Liver dysfunction
    • Hyperinsulinism-Hyperammonaemia Syndrome


    ↓ in:

    • Hypoadrenalism
    • Hypopituitarism
    • ACTH deficiency

    Insulin & C-peptide

    Any detectable insulin in the presence of a BGL <2.6 mmol/L is inappropriate

    Growth hormone

    ↓ in:

    • GH deficiency
    • Panhypopituitarism

    Amino acids

    Amino acid disorders


    Adrenal disorders

    Liver function tests

    Liver disease
    Metabolic defects





    ↓ in 

    • Fatty acid oxidation defect
    • Hyperinsulinaemia

    Reducing substances



     Glucagon IM or S/C:

    • Neonate: glucagon 0.03-0.1 mg/kg (max 1 mg)#
    • <25 kg: give 0.5 mg (½ vial / 0.5 ml)
    • ≥25 kg: give 1.0 mg (1 vial / 1 ml)

      Re-constitute the full 1 mg vial in 1 mL of H2O and then use an insulin syringe to draw up to the 1 'unit' mark on the insulin syringe = 10 mcg of reconstituted glucagon solution

      #  Some infants of diabetic mothers may require up to 0.3 mg/kg to a maximum dose of 1 mg

    Last Updated November 2019

  • Reference List

    1. American Academy of Pediatrics, Adamkin DH C on fetus and newborn. Postnatal Glucose Homeostasis in Late-Preterm and Term Infants. Pediatrics. 2011;127(3):575-579. doi:10.1542/peds.2010-3851
    2. Chandrasekharan P, Lakshminrusimha S. The effectiveness of oral dextrose gel for the treatment of neonatal hypoglycaemia remains unclear. Evid Based Nurs. 2017;20(3):80-81. doi:10.1136/eb-2016-102466
    3. Clinical Q, Queensland G. Queensland Maternity and Neonatal Clinical Guideline: Early onset Group B streptococcal disease. 2010;(November).
    4. Faustino EVS, Hirshberg EL, Bogue CW. Hypoglycemia in critically ill children. J Diabetes Sci Technol. 2012;6(1):48-57. doi:10.1177/193229681200600107
    5. Hegarty JE, Harding JE, Crowther CA, Brown J, Alsweiler J. Oral dextrose gel to prevent hypoglycaemia in at-risk neonates. Cochrane Database Syst Rev. 2017;(7). doi:10.1002/14651858.CD012152.pub2
    6. J WP, Deborah H, Malcolm B, Julie B, Jo H, E HJ. Oral dextrose gel for the treatment of hypoglycaemia in newborn infants. Cochrane Database Syst Rev. 2014;(3). doi:10.1002/14651858.CD011027
    7. Postnatal Glucose Homeostasis in Late-Preterm and Term Infants. Pediatrics. 2011;127(3):575-579. doi:10.1542/peds.2010-3851
    8. Queensland Clinical Guidelines. Maternity and Neonatal Clinical Guideline: Neonatal hypoglycaemia. 2013.
    9. Rozance P. Management and outcomes of neonatal hypoglycemia. Up to Date. 2016:1-38.
    10. Stanley CA, Rozance PJ, Thornton PS, et al. Re-evaluating “transitional neonatal hypoglycemia”: Mechanism and implications for management. J Pediatr. 2015;166(6):1520-1525.e1. doi:10.1016/j.jpeds.2015.02.045
    11. Strategy S, Is HOW, Hypoglycemia N. Screening guidelines for newborns at risk for. Paediatr Child Heal. 2004;9(10):723-729.
    12. Sunehag A, Haymond MW, Wolfsdorf JI. Approach to hypoglycemia in infants and children Authors Section Editor. 2010:1-37.
    13. Sunehag A, Haymond MW. Causes of hypoglycemia in infants and children. UpToDate. 2018.
    14. Thornton PS, Stanley CA, De Leon DD, et al. Recommendations from the Pediatric Endocrine Society for Evaluation and Management of Persistent Hypoglycemia in Neonates, Infants, and Children. J Pediatr. 2015;167(2):238-245. doi:10.1016/j.jpeds.2015.03.057
    15. Wight N, Marinelli KA. ABM Clinical Protocol #1: Guidelines for Blood Glucose Monitoring and Treatment of Hypoglycemia in Term and Late-Preterm Neonates, Revised 2014. Breastfeed Med. 2014;9(4):173-179. doi:10.1089/bfm.2014.9986
    16. Wolfsdorf JI. Pathogenesis , screening , and diagnosis of neonatal hypoglycemia. 2019:1-13.